Home LiteratureArticle Details
PMID: 21494783 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

TGF-β signaling in breast cancer cell invasion and bone metastasis.

Journal of mammary gland biology and neoplasia ·Vol. 16 ·No. 2 ·2011-06-00 ·Pages 97-108

Drabsch Y, ten Dijke P

Abstract

The contribution of transforming growth factor β (TGF-β) signaling to breast cancer has been studied for more than two decades. In an early phase TGF-β may act as a tumour suppressor, while later, when cells have become resistant to its anti-mitogenic effects, the role of TGF-β switches towards malignant conversion and progression. TGF-β stimulates cell invasion and modifies the microenvironment to the advantage of cancer cells. Studies have shown that TGF-β promotes bone and lung metastasis via different mechanisms. The therapeutic strategies to target the TGF-β pathway in breast cancer are becoming increasingly clear. This review will focus on the role TGF-β in breast cancer invasion and metastasis.

MeSH Terms
Animals Bone Neoplasms/metabolism,secondary Breast Neoplasms/metabolism,pathology Female Humans Neoplasm Invasiveness Transforming Growth Factor beta/metabolism
Chemicals
Transforming Growth Factor beta
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Drabsch Yvette
Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands. [email protected]
ten Dijke Peter
References (125)
125 references, click to expand
  1. Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3.
    Mol Cell Biol. 2003 Dec;23(23):8878-89 PMID: 14612425
  2. TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer.
    J Clin Invest. 2010 Jan;120(1):290-302 PMID: 19955655
  3. Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis?
    Curr Pharm Des. 2010;16(11):1291-300 PMID: 20166979
  4. Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression.
    Oncogene. 2010 Dec 9;29(49):6485-98 PMID: 20802523
  5. ID genes mediate tumor reinitiation during breast cancer lung metastasis.
    Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19506-11 PMID: 18048329
  6. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition.
    Nat Cell Biol. 2009 Aug;11(8):943-50 PMID: 19597490
  7. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
    Oncogene. 2005 Jul 28;24(32):5053-68 PMID: 15856015
  8. TGF-beta signaling in cancer--a double-edged sword.
    Trends Cell Biol. 2001 Nov;11(11):S44-51 PMID: 11684442
  9. 17-Beta-estradiol inhibits transforming growth factor-beta signaling and function in breast cancer cells via activation of extracellular signal-regulated kinase through the G protein-coupled receptor 30.
    Mol Pharmacol. 2008 Dec;74(6):1533-43 PMID: 18768737
  10. Beta-casein-derived peptides, produced by bacteria, stimulate cancer cell invasion and motility.
    EMBO J. 2003 Nov 17;22(22):6161-73 PMID: 14609961
  11. Clinical, cellular, and molecular aspects of cancer invasion.
    Physiol Rev. 2003 Apr;83(2):337-76 PMID: 12663862
  12. Concordant epigenetic silencing of transforming growth factor-beta signaling pathway genes occurs early in breast carcinogenesis.
    Cancer Res. 2007 Dec 15;67(24):11517-27 PMID: 18089780
  13. Recent advances in osteoclast biology and pathological bone resorption.
    Histol Histopathol. 2004 Jan;19(1):189-99 PMID: 14702187
  14. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4.
    Breast Cancer Res Treat. 2010 Nov;124(2):377-86 PMID: 20182795
  15. TGF-beta activates Erk MAP kinase signalling through direct phosphorylation of ShcA.
    EMBO J. 2007 Sep 5;26(17):3957-67 PMID: 17673906
  16. The polarization of immune cells in the tumour environment by TGFbeta.
    Nat Rev Immunol. 2010 Aug;10(8):554-67 PMID: 20616810
  17. Friends or foes - bipolar effects of the tumour stroma in cancer.
    Nat Rev Cancer. 2004 Nov;4(11):839-49 PMID: 15516957
  18. Origin of carcinoma associated fibroblasts.
    Cell Cycle. 2009 Feb 15;8(4):589-95 PMID: 19182519
  19. The tumor suppressor Smad4 is required for transforming growth factor beta-induced epithelial to mesenchymal transition and bone metastasis of breast cancer cells.
    Cancer Res. 2006 Feb 15;66(4):2202-9 PMID: 16489022
  20. Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.
    PLoS One. 2009 Sep 03;4(9):e6896 PMID: 19727403
  21. Tumor-host interactions: a far-reaching relationship.
    J Clin Oncol. 2010 Sep 10;28(26):4022-8 PMID: 20644094
  22. Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis.
    Oncogene. 2010 Mar 4;29(9):1351-61 PMID: 20010874
  23. Modeling metastasis in the mouse.
    Curr Opin Pharmacol. 2010 Oct;10(5):571-7 PMID: 20598638
  24. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.
    Cancer Cell. 2008 Jan;13(1):23-35 PMID: 18167337
  25. Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells.
    Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6340-5 PMID: 20308542
  26. TGF-beta and cancer.
    Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 PMID: 16289860
  27. ALCAM, activated leukocyte cell adhesion molecule, influences the aggressive nature of breast cancer cells, a potential connection to bone metastasis.
    Anticancer Res. 2010 Apr;30(4):1163-8 PMID: 20530423
  28. Autocrine TGF-beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts.
    Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20009-14 PMID: 21041659
  29. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.
    Curr Pharm Des. 2010;16(27):3015-27 PMID: 20722621
  30. Transient tumor-fibroblast interactions increase tumor cell malignancy by a TGF-Beta mediated mechanism in a mouse xenograft model of breast cancer.
    PLoS One. 2010 Mar 23;5(3):e9832 PMID: 20352126
  31. Reversibility of epithelial-mesenchymal transition (EMT) induced in breast cancer cells by activation of urokinase receptor-dependent cell signaling.
    J Biol Chem. 2009 Aug 21;284(34):22825-33 PMID: 19546228
  32. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression.
    Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):14028-33 PMID: 19667198
  33. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?
    Endocr Relat Cancer. 2010 Apr 21;17(2):R123-39 PMID: 20335308
  34. Integrative genomic analyses of CXCR4: transcriptional regulation of CXCR4 based on TGFbeta, Nodal, Activin signaling and POU5F1, FOXA2, FOXC2, FOXH1, SOX17, and GFI1 transcription factors.
    Int J Oncol. 2010 Feb;36(2):415-20 PMID: 20043076
  35. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition.
    J Biol Chem. 2008 Nov 28;283(48):33437-46 PMID: 18832382
  36. A novel approach for the generation of genetically modified mammary epithelial cell cultures yields new insights into TGFβ signaling in the mammary gland.
    Breast Cancer Res. 2010;12(5):R83 PMID: 20942910
  37. Cell polarity in motion: redefining mammary tissue organization through EMT and cell polarity transitions.
    J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):149-68 PMID: 20461450
  38. TGF-beta signaling in breast cancer.
    Ann N Y Acad Sci. 2006 Nov;1089:119-26 PMID: 17261761
  39. Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer.
    J Bone Miner Res. 2006 Jul;21(7):1045-59 PMID: 16813525
  40. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
    J Clin Invest. 1999 Jan;103(2):197-206 PMID: 9916131
  41. The tumor-promoting effect of wounding: a possible role for TGF-beta-induced stromal alterations.
    Crit Rev Oncog. 1994;5(2-3):297-311 PMID: 7849089
  42. Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis.
    Mol Cancer. 2010 May 26;9:122 PMID: 20504320
  43. New signals from the invasive front.
    Nature. 2006 May 25;441(7092):444-50 PMID: 16724056
  44. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors.
    J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36 PMID: 7806579
  45. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients.
    Clin Cancer Res. 2007 Sep 1;13(17):5001-9 PMID: 17785550
  46. TGF-β in cancer and bone: implications for treatment of bone metastases.
    Bone. 2011 Jan;48(1):23-9 PMID: 20699127
  47. Global trends in breast cancer incidence and mortality.
    Salud Publica Mex. 2009;51 Suppl 2:s141-6 PMID: 19967268
  48. Inflammation and cancer: breast cancer as a prototype.
    Breast. 2007 Dec;16 Suppl 2:S27-33 PMID: 17764938
  49. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis.
    BMC Cancer. 2007 Mar 27;7:55 PMID: 17389037
  50. Host microenvironment in breast cancer development: extracellular matrix-stromal cell contribution to neoplastic phenotype of epithelial cells in the breast.
    Breast Cancer Res. 2003;5(3):130-5 PMID: 12793893
  51. Non-Smad TGF-beta signals.
    J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84 PMID: 16105881
  52. Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study.
    Breast Cancer Res Treat. 2008 Jul;110(1):39-49 PMID: 17674196
  53. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
    Cancer Res. 2007 Sep 15;67(18):8742-51 PMID: 17875715
  54. BMP7 influences proliferation, migration, and invasion of breast cancer cells.
    Cancer Lett. 2009 Mar 8;275(1):35-43 PMID: 18980801
  55. TGF-beta-induced epithelial to mesenchymal transition.
    Cell Res. 2009 Feb;19(2):156-72 PMID: 19153598
  56. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis.
    Cancer Res. 2010 Jul 15;70(14):6059-70 PMID: 20570898
  57. Epithelial-mesenchymal transitions: twist in development and metastasis.
    Cell. 2004 Aug 6;118(3):277-9 PMID: 15294153
  58. TGF-beta and BMP7 interactions in tumour progression and bone metastasis.
    Clin Exp Metastasis. 2007;24(8):609-17 PMID: 18008174
  59. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
    Cancer Sci. 2009 Jan;100(1):71-81 PMID: 19038005
  60. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis.
    Nature. 2007 Oct 4;449(7162):557-63 PMID: 17914389
  61. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
    J Bone Miner Res. 2001 Jun;16(6):1077-91 PMID: 11393785
  62. Epithelial-mesenchymal transition and cell cooperativity in metastasis.
    Cancer Res. 2009 Sep 15;69(18):7135-9 PMID: 19738043
  63. Healthy lifestyle on the risk of breast cancer.
    Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):912-22 PMID: 21335508
  64. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia.
    Science. 2004 Feb 6;303(5659):848-51 PMID: 14764882
  65. Expression of TGF-beta signaling factors in invasive breast cancers: relationships with age at diagnosis and tumor characteristics.
    Breast Cancer Res Treat. 2010 Jun;121(3):727-35 PMID: 19937272
  66. Transforming growth factor-beta in breast cancer: too much, too late.
    Breast Cancer Res. 2009;11(1):202 PMID: 19291273
  67. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
    Cancer Res. 2006 Feb 15;66(4):2250-6 PMID: 16489028
  68. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.
    Nat Rev Mol Cell Biol. 2003 Aug;4(8):657-65 PMID: 12923528
  69. Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression.
    J Biol Chem. 2006 Aug 25;281(34):24171-81 PMID: 16815840
  70. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment.
    Cancer Res. 2008 Mar 15;68(6):1809-19 PMID: 18339861
  71. Transforming growth factor-beta signaling in epithelial-mesenchymal transition and progression of cancer.
    Proc Jpn Acad Ser B Phys Biol Sci. 2009;85(8):314-23 PMID: 19838011
  72. TGFbeta in Cancer.
    Cell. 2008 Jul 25;134(2):215-30 PMID: 18662538
  73. Endoglin in angiogenesis and vascular diseases.
    Angiogenesis. 2008;11(1):79-89 PMID: 18283546
  74. The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression.
    Oncogene. 2010 Feb 4;29(5):662-73 PMID: 19966854
  75. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity.
    J Biol Chem. 2001 Dec 14;276(50):46707-13 PMID: 11590169
  76. TGF-β1 and BRCA2 expression are associated with clinical factors in breast cancer.
    Cell Biochem Biophys. 2011 Jul;60(3):245-8 PMID: 21222048
  77. Bone morphogenetic protein 7 expression associates with bone metastasis in breast carcinomas.
    Ann Oncol. 2008 Feb;19(2):308-14 PMID: 17895257
  78. Cancer invasion and metastasis: interacting ecosystems.
    Virchows Arch. 2009 Jun;454(6):599-622 PMID: 19471961
  79. Regulation of in situ to invasive breast carcinoma transition.
    Cancer Cell. 2008 May;13(5):394-406 PMID: 18455123
  80. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
    Bone. 2009 Feb;44(2):380-6 PMID: 19041433
  81. Three-dimensional culture models of normal and malignant breast epithelial cells.
    Nat Methods. 2007 Apr;4(4):359-65 PMID: 17396127
  82. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas.
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007 Jun;151(1):59-64 PMID: 17690741
  83. The role of the TGF-β coreceptor endoglin in cancer.
    ScientificWorldJournal. 2010 Dec 14;10:2367-84 PMID: 21170488
  84. Non-Smad pathways in TGF-beta signaling.
    Cell Res. 2009 Jan;19(1):128-39 PMID: 19114990
  85. Identification of breast cancer metastasis-associated genes by chip technology.
    Anticancer Res. 2001 Nov-Dec;21(6A):3799-806 PMID: 11911250
  86. Direct evidence for epithelial-mesenchymal transitions in breast cancer.
    Cancer Res. 2008 Feb 1;68(3):937-45 PMID: 18245497
  87. TGF-beta signaling and the fibrotic response.
    FASEB J. 2004 May;18(7):816-27 PMID: 15117886
  88. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.
    J Biol Chem. 2002 Jul 5;277(27):24571-8 PMID: 11964407
  89. The TGF-β/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system.
    Breast Cancer Res Treat. 2011 Aug;128(3):657-66 PMID: 20821046
  90. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1.
    Nat Cell Biol. 2008 May;10(5):593-601 PMID: 18376396
  91. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition.
    J Cell Biol. 2006 Jul 17;174(2):175-83 PMID: 16831886
  92. The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling.
    J Clin Invest. 2009 Sep;119(9):2678-90 PMID: 19726885
  93. TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
    Exp Cell Res. 2008 Nov 15;314(19):3478-93 PMID: 18848540
  94. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
    J Clin Invest. 2006 Oct;116(10):2777-90 PMID: 17016559
  95. Molecular biology of bone metastasis.
    Mol Cancer Ther. 2007 Oct;6(10):2609-17 PMID: 17938257
  96. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
    Genes Dev. 2009 Aug 15;23(16):1882-94 PMID: 19608765
  97. Homeoprotein Six1 increases TGF-beta type I receptor and converts TGF-beta signaling from suppressive to supportive for tumor growth.
    Cancer Res. 2010 Dec 15;70(24):10371-80 PMID: 21056993
  98. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.
    Gynecol Oncol. 2011 May 1;121(2):353-7 PMID: 21324516
  99. Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration.
    J Biol Chem. 2000 Nov 24;275(47):36803-10 PMID: 10969078
  100. Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility.
    Nat Cell Biol. 2009 Nov;11(11):1287-96 PMID: 19838175
  101. Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness.
    Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18721-6 PMID: 17130448
  102. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.
    Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13909-14 PMID: 16172383
  103. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells.
    J Cell Sci. 1999 Dec;112 ( Pt 24):4557-68 PMID: 10574705
  104. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
    Mol Cancer Res. 2008 Oct;6(10):1521-33 PMID: 18922968
  105. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling.
    Cancer Res. 2011 Feb 1;71(3):822-31 PMID: 21189326
  106. The influence of the microenvironment on the malignant phenotype.
    Mol Med Today. 2000 Aug;6(8):324-9 PMID: 10904250
  107. Gene-environment interactions in 7610 women with breast cancer: prospective evidence from the Million Women Study.
    Lancet. 2010 Jun 19;375(9732):2143-51 PMID: 20605201
  108. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
    J Clin Invest. 1996 Oct 1;98(7):1544-9 PMID: 8833902
  109. CCN5, a novel transcriptional repressor of the transforming growth factor β signaling pathway.
    Mol Cell Biol. 2011 Apr;31(7):1459-69 PMID: 21262769
  110. Radiation-induced transforming growth factor beta and subsequent extracellular matrix reorganization in murine mammary gland.
    Cancer Res. 1993 Sep 1;53(17):3880-6 PMID: 8358713
  111. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.
    J Mammary Gland Biol Neoplasia. 2010 Jun;15(2):117-34 PMID: 20490631
  112. TGF-beta signaling: positive and negative effects on tumorigenesis.
    Curr Opin Genet Dev. 2002 Feb;12(1):22-9 PMID: 11790550
  113. Molecular characterization of TGFbeta-induced epithelial-mesenchymal transition in normal finite lifespan human mammary epithelial cells.
    Biochem Biophys Res Commun. 2010 Sep 3;399(4):659-64 PMID: 20691661
  114. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.
    Cancer Res. 1991 Jun 1;51(11):3059-61 PMID: 2032246
  115. New insights into TGF-beta-Smad signalling.
    Trends Biochem Sci. 2004 May;29(5):265-73 PMID: 15130563
  116. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.
    Immunol Rev. 2008 Apr;222:162-79 PMID: 18364001
  117. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis.
    Nat Med. 2009 Aug;15(8):960-6 PMID: 19597504
  118. Human mammary fibroblasts stimulate invasion of breast cancer cells in a three-dimensional culture and increase stroma development in mouse xenografts.
    BMC Cancer. 2010 Aug 19;10:444 PMID: 20723242
  119. TGF-β regulates isoform switching of FGF receptors and epithelial-mesenchymal transition.
    EMBO J. 2011 Feb 16;30(4):783-95 PMID: 21224849
  120. TGF beta inhibition for cancer therapy.
    Curr Cancer Drug Targets. 2006 Nov;6(7):565-78 PMID: 17100564
  121. Endoglin expression in breast tumor cells suppresses invasion and metastasis and correlates with improved clinical outcome.
    Oncogene. 2011 Mar 3;30(9):1046-58 PMID: 21042283
  122. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4.
    Cell. 2008 Apr 4;133(1):66-77 PMID: 18394990
  123. TGF-beta and epithelial-to-mesenchymal transitions.
    Oncogene. 2005 Aug 29;24(37):5764-74 PMID: 16123809
  124. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells.
    Cancer Res. 2000 Mar 1;60(5):1254-60 PMID: 10728684
  125. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA.
    Mol Biol Cell. 2002 Mar;13(3):902-14 PMID: 11907271
Article Info
Journal
Journal of mammary gland biology and neoplasia
Abbr.
J Mammary Gland Biol Neoplasia
ISSN
1573-7039
DOI
10.1007/s10911-011-9217-1
Email
[email protected]
Published
2011-06-00
Epub
2011-00-15
Pages
97-108
Language
English
Region
United States
NLM ID
9601804
PMCID
PMC3095797
Subset
IM
External Links
PubMed source DOI: 10.1007/s10911-011-9217-1 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2